LUCD Lucid Diagnostics: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

The price visualization on GURU.Markets shows that Lucid Diagnostics Inc. (LUCD) has an EV/EBITDA of 0.00, while the business relies on a single diagnostic system and anticipates an expansion in insurance reimbursements. Lucid Diagnostics Inc. (LUCD) is implementing EsoGuard AI technologies to detect gastrointestinal oncology via DNA markers. The standardization of such tests in clinics guarantees a steady client inflow and regular profits from the sale of consumables.

Lucid Diagnostics Inc - LUCD Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/10/2026)

luciddx.com (LUCD) - metric breakdowns and financial figures

- stock price and consensus target price:

Stock Quotes Lucid Diagnostics Inc|LUCD - Average Forecast Price

- company stock capitalization data:

Market Value Lucid Diagnostics, Inc|LUCD - Company Buyout Price

- book value of equity indicators:

Book Value per Share Lucid Diagnostics|LUCD - Book Valuation of Business|Market Value to Book Value Ratio luciddx.com|LUCD - Company Total Asset Base

- company liabilities and liquidity data:

- financial results and valuation multiples details:

LUCD - Company Profit|Future Profit Lucid Diagnostics Inc.|LUCD - Company Value to Net Income|Forward P/E Multiple Lucid Diagnostics Inc.|LUCD - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Lucid Diagnostics, Inc|LUCD - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Lucid Diagnostics|LUCD - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth luciddx.com|LUCD - Net earnings per share change in current year|Net earnings per share growth forecast for next year Lucid Diagnostics Inc.

Fundamental company analysis:Lucid Diagnostics Inc LUCD

Original product of Lucid Diagnostics, Inc.

When screening for issuer reliability, this indicator serves as a filter for asset overvaluation. It correlates the total enterprise value (market capitalization plus net debt) with operating profit before depreciation and amortization, reflecting the actual cost of cash flow generation. For Lucid Diagnostics Inc. (LUCD), given its volatile revenue from cancer tests, this metric reveals the risk of an inflated valuation. By analyzing the EV/EBITDA ratio trajectory, an investor can determine the asset's overheating point.

Competitors of Lucid Diagnostics Inc. (LUCD)

Agilent Tech - Enterprise Value to EBITDA Ratio|Quest Corp (DGX) - Company Value to EBITDA|ILMN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio exactsciences.com EXAS|RVTY: EV/EBITDA Multiple|BIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Anbio Tech|Nordion (SHC) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization QuidelOrtho (QDEL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization OPK (opko.com)|CareDx Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Maravai LifeSciences Holdings MRVI|Fulgent Corp - EV/EBITDA Multiple|Standard BioTools Corp (LAB) - Enterprise Value to EBITDA Ratio|CTKB: EV/EBITDA Multiple|OSUR - Total Company Value to Operating Income Before Depreciation Ratio|XGN (Exagen Inc) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation MDXH (MDxHealth S.A.)|Enterprise Value to EBITDA Ratio PRE (Prenetics Global)|IMDX (imdxinc.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TRIB (Trinity Biotech)|PRPH: Enterprise Value to Operating Income Before Depreciation|Ainos - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Co-Diagnostics Inc CODX|HSCS: EV/EBITDA Multiple|Biomerica Inc (BMRA) - EV/EBITDA Multiple|CDIO (Cardio Diagnostics Holdings Inc.) - EV/EBITDA Multiple|ONCO - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Virax Biolabs (VRAX)|Bluejay Diagnostics Inc - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Company Value to EBITDA|CNTG - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Enzo Biochem, Inc. ENZ|FRES (fresh2.co) - Enterprise Value to EBITDA Ratio|GENE: Enterprise Value to Operating Income Before Depreciation Ratio|ME (23andMe Inc.) - EV/EBITDA Multiple|Psychemedics Inc (PMD) - Total Company Value to Operating Income Before Depreciation Ratio